Literature DB >> 8355677

Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.

T Unger1, J A Mietz, M Scheffner, C L Yee, P M Howley.   

Abstract

The wild-type (wt) p53 protein has transcriptional activation functions which may be linked to its tumor suppressor activity. Many mutant p53 proteins expressed in cancers have lost the ability to function as transcriptional activators and furthermore may inhibit wt p53 function. To study the mechanisms by which mutant forms of p53 have lost their transactivation function and can act in a dominant negative manner, a structure-function analysis of both mutant and engineered truncated forms of p53 was carried out. We show that different mutant p53 proteins found in cancers vary in the ability to inhibit the transcriptional transactivation and specific DNA binding activities of wt human p53. This transdominant effect was mediated through the carboxy-terminal oligomerization region. The role of the transactivation activity in transformation suppression by wt p53 was also examined by constructing an N-terminal deletion mutant lacking the transactivation domain. This mutant was unable to transactivate but could bind specifically to DNA. Although it was impaired in its ability to suppress transformation of primary rat embryo fibroblasts by adenovirus E1A plus activated ras, the N-terminal deletion mutant still had some suppression activity, suggesting that additional functions of p53 may contribute to transformation suppression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355677      PMCID: PMC360207          DOI: 10.1128/mcb.13.9.5186-5194.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  60 in total

1.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

Authors:  J Milner; E A Medcalf
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

2.  The MCK enhancer contains a p53 responsive element.

Authors:  H Weintraub; S Hauschka; S J Tapscott
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

3.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Identification of p53 as a sequence-specific DNA-binding protein.

Authors:  S E Kern; K W Kinzler; A Bruskin; D Jarosz; P Friedman; C Prives; B Vogelstein
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

7.  Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.

Authors:  U Santhanam; A Ray; P B Sehgal
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

8.  A potential transcriptional activation element in the p53 protein.

Authors:  R W O'Rourke; C W Miller; G J Kato; K J Simon; D L Chen; C V Dang; H P Koeffler
Journal:  Oncogene       Date:  1990-12       Impact factor: 9.867

9.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

Authors:  P W Hinds; C A Finlay; R S Quartin; S J Baker; E R Fearon; B Vogelstein; A J Levine
Journal:  Cell Growth Differ       Date:  1990-12

10.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.

Authors:  E Yonish-Rouach; D Resnitzky; J Lotem; L Sachs; A Kimchi; M Oren
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

View more
  33 in total

1.  Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.

Authors:  Y Nie; H H Li; C M Bula; X Liu
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

2.  Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.

Authors:  F Janus; N Albrechtsen; U Knippschild; L Wiesmüller; F Grosse; W Deppert
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

3.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

4.  Replication of damaged DNA in vitro is blocked by p53.

Authors:  Jianmin Zhou; Carol Prives
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

5.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.

Authors:  T Unger; T Juven-Gershon; E Moallem; M Berger; R Vogt Sionov; G Lozano; M Oren; Y Haupt
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

6.  Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53.

Authors:  A L Okorokov; F Ponchel; J Milner
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

7.  The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific.

Authors:  Jennifer M Smith; Lawton J Stubbert; Jeffrey D Hamill; Bruce C McKay
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

8.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.

Authors:  Josephine C Ferreon; Chul Won Lee; Munehito Arai; Maria A Martinez-Yamout; H Jane Dyson; Peter E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

9.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  The activation region of the Tat protein of human immunodeficiency virus type-1 functions in yeast.

Authors:  T Subramanian; C D'Sa-Eipper; B Elangovan; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.